Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab after ASCT for Multiple Myeloma
NCT02331368Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2015
- Primary completion
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in multiple myeloma (MM), sponsored by University of Michigan Rogel Cancer Center. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02331368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02331368.